Immunotherapy after liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy after surgery to remove liver cancer can help lower the risk of the cancer coming back. It may be an option for people who have certain risk factors for recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible liver cancer.
- Your cancer was confirmed as liver cancer by a biopsy or after surgery.
- Your liver is still working well enough (Child-Pugh class A or B).
- You are physically active and able to take care of yourself (performance status 0 or 1).
- You have at least one high-risk feature, such as a tumor 5 cm or larger, multiple tumors, or cancer in blood vessels.
- You have not received immunotherapy as a first treatment before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.